[{"orgOrder":0,"company":"Shanghai United Cell Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Recombinant Subunit B Bacterial Cholera Vaccine","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Shanghai United Cell Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai United Cell Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai United Cell Biotechnology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Shanghai United Cell Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Showcase
                          Not Confirmed
                          Biotech Showcase
                          Not Confirmed

                          Details : Recombinant Subunit B Bacterial Cholera Vaccine is a vaccine drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Diarrhea.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 23, 2025

                          Lead Product(s) : Recombinant Subunit B Bacterial Cholera Vaccine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank